The pharmacokinetics of metoprolol and its metabolites in dialysis patients.
The kinetics of tritiated metoprolol and its metabolites have been determined after intravenous and oral administration in dialysis patients. The kinetic behaviour of metoprolol in these patients does not differ from that in healthy volunteers, since its elimination depends on hepatic metabolism. The pharmacologically less active metabolite alpha-hydroxymetoprolol is formed to an individually varying degree and its half-life is prolonged. The concentration of the total radioactivity, which represents the sum of all metabolites, does not decline in the dialysis interval. During haemodialysis, however, its concentration decreases with a half-life of 5h. It might be assumed, that dialysis of these polar compounds is rather nonspecific and that it depends essentially on the dialysis technique.
D000328:Adult; D000368:Aged; D001262:Atenolol / Q000378:metabolism; D001711:Biotransformation; D005260:Female; D006207:Half-Life; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood / Q000378:metabolism*; D007700:Kinetics; D008297:Male; D008657:Metabolic Clearance Rate; D008790:Metoprolol / Q000097:blood / Q000378:metabolism*; D008875:Middle Aged; D011412:Propanolamines / Q000378:metabolism*; D006435:Renal Dialysis
D011412:Propanolamines; D001262:Atenolol; D008790:Metoprolol